Last reviewed · How we verify
GLR2007
At a glance
| Generic name | GLR2007 |
|---|---|
| Also known as | GLR2007-237FA |
| Sponsor | Gan and Lee Pharmaceuticals, USA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of GLR2007 for Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLR2007 CI brief — competitive landscape report
- GLR2007 updates RSS · CI watch RSS
- Gan and Lee Pharmaceuticals, USA portfolio CI